Key people
In the news
- Obulytix at the IHI Forum 2026 in Brussels Last week, Lucia Grassi attended the Innovative Health Initiative (IHI) Forum in Brussels, bringing together researchers, industry representatives and healthcare innovators to explore how public-private partnerships can accelerate innovation in healthcare. As part of the END2AMR project, Lucia presented a scientific poster entitled “Improved candidate selection through wound-relevant evaluation of Precision Lysin Therapeutics.” Her work highlights how Obulytix is contributing to the
- October is 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵 — an opportunity to highlight the importance of infection control throughout cancer care. Cancer patients, including those undergoing treatment for breast cancer, are at significantly increased risk of multidrug-resistant bacterial infections. Large U.S. studies have shown antimicrobial-resistant infections occur up to three times more frequently in cancer patients than in non-cancer populations, with some resistant pathogens occurring more than five times as
- Last week, Maria Fonseca joined #BostonBiotechWeek and #RESI in Boston on behalf of Obulytix, connecting with investors, biotech entrepreneurs, researchers, and industry leaders from across the life sciences ecosystem. A particular highlight was sharing the experience with the Belgian biotech delegation and exchanging perspectives on the challenges and opportunities of translating innovation from bench to patient in our local ecosystem. At RESI, organized by Life Science Nation, we gained valuable insights into US and
- Tomorrow, Dennis Grimon and Maria Fonseca will be attending the kick-off of the Life Sciences Community, organized by Voka Oost-Vlaanderen and hosted by Legend Biotech. We're excited to connect with founders, investors, researchers, and industry leaders across medical biotech, industrial biotech, and agtech, and to contribute to shaping the future of the life sciences ecosystem in Flanders. Will you be there too? We'd love to connect and exchange ideas. #LifeSciences #Biotech #Innovation #Networking #Voka #LifeSciencesCommunity
- Today, our CEO, Kristof Van Emelen, took the stage at BioCentury Inc. Grand Rounds: Europe to present Obulytix’s work on Precision Lysin Therapeutics (PLTs), a novel modality addressing one of today’s most pressing issues, antibiotic resistance. Capable of fast killing under real world conditions, PLTs present a transformational solution that delivers meaningful efficacy without fueling resistance. #Obulytix #AMR #AntimicrobialResistance #Biotech #DrugDevelopment #LifeSciences #PrecisionLysinTherapeutics #BioCenturyGrandRounds
- Next week, Obulytix is on the move. 🌍 From Amsterdam to Lisbon and Boston, members of our team will be connecting with the international biotech and #AMR community, while our colleagues in #Ghent continue to move our science forward in the lab. Amsterdam 🇳🇱 Kristof Van Emelen and Henrik Luessen are excited to be presenting our science at the 2nd BioCentury Inc. Grand Rounds Steering Committee, which connects translational science with the right partners to advance drug development. Lisbon 🇵🇹 Guy Hermans will attend @GAMRIC
- Next-generation antibiotics development data release upcoming! 🚀 #GAMRIC2026 has designated Obulytix's poster as one of the top-rated abstracts in the 𝑁𝑒𝑤 𝑎𝑛𝑡𝑖𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎𝑙 𝑜𝑟 𝑎𝑛𝑡𝑖𝑓𝑢𝑛𝑔𝑎𝑙 𝑐𝑙𝑎𝑠𝑠𝑒𝑠 category. If you attend #GAMRIC2026 in Lisbon on 𝟐𝟐-𝟐𝟒 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟔, come see our CSO Guy Hermans at our poster "𝑆𝑦𝑠𝑡𝑒𝑚𝑎𝑡𝑖𝑐 𝑒𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑖𝑛𝑔 𝑜𝑓 𝑙𝑦𝑠𝑖𝑛𝑠 𝑦𝑖𝑒𝑙𝑑𝑠 𝑠𝑒𝑟𝑢𝑚-𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑡 𝑎𝑛𝑑 𝑖𝑛 𝑣𝑖𝑣𝑜 𝑎𝑐𝑡𝑖𝑣𝑒 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑𝑠 𝑡𝑜𝑤𝑎𝑟𝑑𝑠
- The first half of 2026 has been an exciting and productive period for Obulytix. Over the past months, we had the opportunity to connect with scientists, clinicians, biotech innovators, investors and industry leaders across several key international events focused on infectious diseases and antimicrobial resistance and beyond. 📍AMR Conference 2026 - Basel (March 3-4) We joined one of the leading global conferences dedicated to antimicrobial resistance, where our team presented Obulytix's progress in developing Precision Lysin
Something wrong or missing? Send an update. Fixed within 24 hours.